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Abstract: Two-stage revision has been shown to be the most successful treatment in eradicating deep infection following 
total  hiparthroplasty.  We identified 62 patients treated by a two-stage revision. We defined “successful revision”  as 
negative intraoperative cultures and no further infection-related procedure. We defined “eradication of infection” on the 
basis of negative cultures and clinical diagnosis at least one year after 2
nd stage procedure. After a mean follow up of 2.7 
years, eradication of the infection was documented in 91.1%, and a successful two-stage revision in 85.7% of patients. We 
observed no association between higher pre-reimplantation levels of ESR and C-reactive protein and lower likelihood of 
successful two-stage revision. We found an association between a history of another previous infected prosthetic joint and 
a  failed  2
nd  stage  procedure.  Failure  to  achieve  eradication  of  infection  and  successful  two-stage  revision  occurs 
infrequently. Patients with prior history of a previous prosthetic joint infection are at higher risk of failure. 
Keywords: Hip arthroplasty, modular antibiotic cement spacer, periprosthetic infection, two-stage revision surgery.  
INTRODUCTION 
  Total  hip  arthroplasty  (THA)  has  become  the  gold 
standard treatment for patients with end stage arthritis [1]. 
The  benefits  of  total  hip  arthroplasty  as  a  treatment  for 
arthritis have been well documented. Multiple studies have 
demonstrated  that  following  total  hip  arthroplasty  patients 
experience  significant  quantitative  and  qualitative 
improvement in both their physical function and quality of 
life  [2-4].  Utilization  of  THA  is  rising  with  current 
projections  in  the  United  States  predicting  an  increase  of 
174% to nearly 600,000 THA procedures annually by 2030 
[5-7]. 
  Postoperative  infection  is  one  of  the  most  devastating 
complications encountered after THA. In the initial studies 
of THA, the lifetime infection rate was found to be 9%-12%, 
and the procedure was nearly abandoned [8]. However, with 
improvement in sterile procedure and preoperative antibiotic 
prophylaxis, the overall lifetime risk of infection has been 
reported to decrease to less than 1% [9]. However, a report 
using Medicare data documented a 1.63% rate of infection in 
THA within the first two years, with most cases presenting 
in the first 4 weeks postoperatively [9]. 
  Treatment  options  for  infected  THA  depend  on  the 
chronicity of the infection, patient comorbidities and type of  
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organism. Treatment options include antibiotic suppression, 
debridement  and  irrigation  and  exchange  of  all  modular 
parts, single-stage revision, two-stage revision, and resection 
arthroplasty  (Girdlestone).  All  of  these  treatments  are 
accompanied by long term intravascular antibiotic treatment 
protocols. 
  Two-stage revision has been shown to yield a high rate of 
infection eradication and survival of the reimplanted THA 
and is the standard of care in North America for infected 
THA [10, 11]. An articulating antibiotic spacer helps deliver 
local  antibiotics,  maintains  joint  mobility,  and  facilitates 
reimplantation by reducing soft tissue contracture and scar 
formation [12]. Studies using a two-stage revision with an 
articulating spacer have reported success rates ranging from 
89%-96% [10, 13, 14]. 
  We report a large series of patients with deep infection 
following THA managed by a single surgeon with a highly 
specialized revision THA referral practice. The surgeon used 
a  standardized  surgical  technique  and  treatment  protocol, 
including  a  custom  intraoperative  fabricated  articulating 
cement  spacer  constructed  from  a  custom-made  mold. 
Intraoperative  fabrication  of  the  cement  spacer  with  a 
customized mold allows the surgeon the freedom of utilizing 
different cement types, choosing the added amount and type 
of  antibiotics,  and  tailoring  the  mold  to  the  patient’s 
anatomy.  This  enables  a  better  femoral  canal  fit  and 
antibiotic  delivery.  We  report  the  rate  of  infection 
eradication  and  successful  two-stage  revision,  as  well  as 
patient and infection characteristics that may predict failure 
or reinfection after two-stage revision THA reimplantation. Treatment Failure Among Infected Periprosthetic Total Hip Arthroplasty Patients  The Open Orthopaedics Journal, 2014, Volume 8    119 
MATERIALS AND METHODS  
Study Design and Selection Criteria 
  This retrospective study was performed after institutional 
IRB approval. The authors reviewed the charts of all patients 
who  had  undergone  two-stage  THA  revision  at  a  single 
institution  by  a  single  surgeon  between  2001-2011.  All 
patients who had undergone a two-stage revision THA for 
periprosthetic  infection  were  included  in  this  study.  A 
diagnosis  of  infection  was  made  by  the  treating  surgeon 
guided  by  the  musculoskeletal  infection  society  (MSIS) 
criteria for the diagnosis of PJI: positive joint fluid cultures, 
joint fluid cell count and differential, inflammatory markers 
(CRP and ESR) presence of a sinus tract, gross purulence 
observed at the time of surgery, and a positive histological 
exam  for  acute  inflammation  in  tissues  obtained  during 
surgery.  We  identified  62  patients  who  were  treated  by  a 
two-stage THA revision for periprosthetic infection by the 
senior author (DE) with a single surgical technique, utilizing 
an  articulating  antibiotic  spacer  fabricated  intraoperatively 
with a customized mold. 
Data Collection 
  Demographic  and  patient  data  were  collected  from 
hospital records for all patients including; BMI, age, gender 
and  infection  markers  (CRP,  ESR).  Infection  data  were 
evaluated by collecting both preoperative and intraoperative 
cultures,  and  synovial  fluid  cell  counts  and  differential. 
Perioperative complications were recorded from the patients’ 
charts. The overall preoperative medical status of the patients 
was  evaluated  by  the  Charlson  comorbidity  index  (22). 
Failure of infection eradication was diagnosed based on both 
positive cultures and clinical diagnosis. 
Surgical Technique 
  A posterior-lateral approach to the hip (Kocher-Langen-
beck) was utilized in all cases, with a joint fluid aspiration 
performed prior to the arthrotomy, followed by an extensive 
synovectomy and explantation of all implants. Perioperative 
antibiotics  were  held  until  the  joint  aspiration  was 
completed. Endosteal membrane was removed from both the 
femoral medullary canal and the acetabulum, and was sent 
for culture and histology. 
  After verification that all remaining cement was debrided 
(if cemented implants were used), a ball tip guide wire was 
placed down the femoral canal. Sequential flexible reamers 
were  used  to  ream  the  femoral  canal  until  sufficient 
endosteal contact was created to remove all retained debris 
and create a bleeding bony surface. At that point we used our 
custom-made  canal  mold  sizers  (Fig.  1)  to  measure  the 
femoral  canal  diameter  (achieving  a  tight  manual  fit). 
Attention  was  shifted  to  the  acetabulum  where  sequential 
reaming  was  conducted  until  a  bleeding  surface  was 
identified.  Then  irrigation  of  both  the  acetabulum  and  the 
femoral canal was carried out using a pulse lavage device; 
first three liters of saline solution were used in the femoral 
canal,  with  a  long  nose  tip,  followed  by  one  liter  of 
bacitracin solution (33,000 units per liter). Subsequently, the 
entire soft tissue envelope and acetabular bony surface were 
irrigated with six liters of saline solution, followed by two 
liters of bacitracin solution (33,000 units per liter). 
 
Fig. (1). Custom-made canal mold sizers. 
  To conserve surgical time, we simultaneously fabricated 
the cement-tapered stem on the back table. Our specialized 
stem mold was used to produce the antibiotic femoral stem 
by coating a modular stem (S-ROM, Depuy, Warsw). The 
femoral head spacer was fabricated by covering a 22 mm 
CoCr head with a cement-molded spacer (fabricated from a 
surgical  irrigation  bulb  syringe).  Our  protocol  includes  
80  grams  (two  packs)  of  polymethylmethacrylate  cement 
(Simplex P; Stryker, Mahwah, NJ), premixed with 1 gram of 
tobramycin  per  40  grams  of  cement.  To  this  we  added  
4.8  grams  of  tobramycin  powder,  and  2  grams  of 
vancomycin powder for a total of 4.4 grams of antibiotics 
per 40 grams of cement powder. For mixing we added a third 
bottle  of  monomer  due  to  the  added  volume  of  the 
antibiotics.  The  cement  was  mixed  and  poured  into  the 
appropriate size tapered stem mold and bulb syringe mold 
(Fig. 2a, b). A femoral modular stem was placed into the 
cement mold (Fig. 3), and a femoral head was placed into the 
syringe  mold  (Fig.  4).  After  full  polymerization  of  the 
cement, the mold and bulb syringe were split and the stem 
and head were removed (Fig. 5a, b). The stem was placed 
appropriately into the femoral canal (Fig. 6). The hip was 
reduced and stability examined. After verification of desired 
anteversion angle the spacer was secured by adding cement 
into the medial calcar flare and coating the exposed body of 
the  implant  to  provide  adequate  rotational  stability.  The 
added  cement  protocol  included  40  grams  (one  pack)  of 
polymethylmethacrylate  cement  (Palacos  R+G;  Zimmer, 
Warsaw,  IN),  premixed  with  0.5  gram  of  gentamycin  per  
40  grams  of  cement.  To  this  we  added  2.4  grams  of 
tobramycin powder, and 1 gram of vancomycin powder for a 
total  of  3.9  grams  of  antibiotics  per  40  grams  of  cement 
powder. The decision to use two different cements for each 
phase  of  the  surgery  is  due  to  their  different  work  time, 
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Palacos has more work time and easier to use for “free hand” 
molding. 
(a) 
 
(b) 
 
Fig. (2). Cement was mixed and poured into the appropriate size 
tapered stem mold (a) and bulb syringe mold (b). 
  Patients  were  allowed  to  partially  weight  bear  on  the 
operated leg with bilateral upper extremity support. Patients 
received culture specific intravenous antibiotic treatment for 
a  period  of  at  least  6  weeks  under  the  supervision  of  an  
 
infectious  diseases  specialist.  Patients  were  followed  with 
serial  inflammatory  markers,  CRP  and  ESR,  during  this 
period. Repeat arthrocentesis was done to monitor cell count 
and  cultures  after  an  antibiotic  free  period  of  at  least  2 
weeks. Surgical wound was monitored during office visits at 
2 weeks and 6 weeks postoperatively, and 1 week prior to 
the planned 2
nd stage reimplantation surgery. Patients were 
monitored  for  complications  related  to  the  procedure  and 
treatment. 
 
Fig. (3). A femoral modular stem is placed into the cement mold. 
 
Fig. (4). A femoral head is placed into the syringe mold before the 
cement curs. 
  Reimplantation was considered between 3-4 months after 
the initial procedure if the hip joint aspiration had a negative 
culture and low cell counts, as well as descending trend of 
inflammatory markers. Revision surgery was completed and 
intraoperative tissue and joint fluid cultures and cell counts 
were taken. 
  We defined “successful two-stage revision” if no further 
surgical  procedures  were  conducted  during  the  follow-up 
period (e.g. irrigation and debridement, explant, Girdlestone, 
amputation, revision THA for non-infectious etiology); this 
was  our  primary  outcome.  We  defined  “eradication  of 
infection” if intraoperative cultures at the time of revision 
surgery  were  negative  and  if  the  patient  had  no  further 
infection  related  procedure  (irrigation  and  debridement, 
explant, etc.) or a diagnosis of periprosthetic joint infection 
in the following year after the 2
nd stage procedure; this was 
our secondary outcome. Treatment Failure Among Infected Periprosthetic Total Hip Arthroplasty Patients  The Open Orthopaedics Journal, 2014, Volume 8    121 
Data Analysis 
  Categorical variables were analyzed using chi-square test 
and Fisher’s exact test. Continuous variables were analyzed 
using  the  t-test  and  Wilcoxon  test.  All  analyses  were 
conducted using SAS software, version 9.1.3 (SAS Institute, 
Carey, NC). 
 (a) 
 
(b) 
 
Fig. (5). After full polymerization of the cement, the mold and bulb 
syringe are split and the stem (a) and head (b) were removed. 
RESULTS 
  Our  study  cohort  consisted  of  62  patients  who  were 
treated  by  a  two-stage  THA  revision  for  periprosthetic 
infection. One patient died from unrelated co-morbidity and 
five patients were lost to follow-up prior to completing the 
2
nd stage procedure. 56 patients were included in the final 
analysis. A Charlson comorbidity index score of 0 or 1 was 
found in 64% of the patients, while 36% had a score of 2 or 
more.  The  median  length  of  time  between  the  patient’s 
primary  THA  surgery  and  the  first  stage  revision  surgery 
was  6.1  years  (range:  1  month  -  35  years).  35  of  these 
patients (63%) had more than one surgery on the infected 
total hip before antibiotic spacer placement and eight had 2, 
four had 3, and four had 4 or more surgeries prior to the 1
st 
stage  revision  and  antibiotic  spacer  placement  at  our 
institution,  these  surgeries  were  performed  by  the  initial 
surgeon prior to presentation at our center (these surgeries 
included failed I&D and revision surgeries). Only 38 of the 
56 patients had complete preoperative cultures compared to 
56  with  complete  intraoperative  cultures.  Staphylococcus 
species  predominated  as  the  organism  responsible  for  the 
infections, with 23.7% of the preoperative cultures positive 
for Staphylococcus species, and 26.9% of the intraoperative 
cultures positive for Staphylococcus species (Table 1). No 
postoperative fractures or dislocations of the customized hip 
spacer occurred among the study cohort. 
 
Fig.  (6).  Postoperative  radiograph  after  placement  of  a  custom 
fabricated femoral mold. 
  Joint  fluid  analysis  revealed  a  median  WBC  count  of 
9.7 cells/µL (range 3.0-23.8 cells/µL) preoperatively. Prior to 
reimplantation median CRP values were 4.5 mg/dL (range 
0.08-489  mg/dL)  and  median  ESR  values  were  25  mm/hr 
(range 2-125 mm/hr). 
  At  final  radiographic  follow-up,  all  X-rays  were 
evaluated and signs of loosening were evaluated: subsidence, 
presence  of  a  bony  pedestal,  lack  of  osseous  integration, 
radiolucent lines around the stem. None of the reimplanted 
components was radiographically loose. 
  After a mean follow-up (after the 2
nd stage revision) of 
2.7  years,  a  successful  2
nd  stage  revision  procedure  was 
performed on 48 (85.7%) of the patients in the final analysis 
cohort  of  56  patients.  Of  the  remaining  8  patients,  6 
underwent Girdlestone, one was lost to follow-up after the 
2
nd stage reimplantation and one underwent only one stage 
due  to  chronic  infection.  Eradication  of  the  infection  was 
documented in 91.1% of the patients, and 80.4% of patients 
experienced both eradication of the presenting infection and 
a successful 2
nd stage procedure (Table 2). A “worse case” 
scenario including the 5 patients that were lost to follow-up 
as  failures  would  drop  our  success  rate  to  78.6%  for  a 
successful 2
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and  73.7%  of  patients  experiencing  both  eradication  of 
infection anda successful 2
nd stage procedure. 
Table 2.  Patients’  outcomes  among  three  end  points: 
successful 2-stage revision, eradication of infection, 
and achieving both a successful 2-stage revision and 
eradication of infection. 
 
Outcome (N=56)  Frequency  (N, %)  95% CI 
2-stage reimplantation  48 (85.7%)  76.5% - 94.9% 
Eradication of infection   51 (91.1%)  83.6% - 98.6% 
2-stage reimplantation + 
 infection eradication   45 (80.4%)  70.0% - 90.8% 
 
  We  found  no  association  between  successful  2
nd  stage 
reimplantation  and  patient  Charlson  comorbidities  index 
(p=0.70) (Table 3). Similarly, no association was found between 
successful 2
nd stage reimplantation and pre-reimplantation levels 
of  ESR  (median  difference  11.2  mm/hr,  p=0.68),  and  CRP 
(median 1.5 mg/dL, p=0.48) (Table 4). 
  We found a suggestion of an association between having 
another infected total joint replacement and a failed 2
nd stage 
procedure (p=0.05) (Table 3). Although not reaching statistical  
 
Table 3.  Association  between  patient  variables,  and  a 
successful 2
nd stage outcome. 
 
Variable 
2
nd Stage  
Success  
(N=48) 
2
nd Stage  
Failure  
(N=8)  p-Value 
N (%)  N (%) 
Sex 
Male 
Female 
 
22 (81.5) 
26 (89.7) 
 
5 (18.5) 
3 (10.3) 
.46 
Charlson Score 
0-1 
≥ 2 
 
30 (83.3) 
18 (90.0) 
 
6 (16.7) 
2 (10.0) 
.70 
OR culture* 
None/other 
MSSA/MRSA 
 
41 (85.4) 
 7 (87.5) 
 
7 (14.6) 
1 (12.5) 
1.0 
OR culture* 
None/other 
MRSA 
 
43 (84.3) 
5 (100) 
 
8 (15.7) 
0 (0) 
1.0 
Secondary surgery prior to explant 
No 
Yes 
 
19 (90.5) 
29 (82.9) 
 
2 (9.5) 
 6 (17.1) 
.70 
Other infected joints 
No 
Yes 
 
44 (89.8) 
 4 (57.4) 
 
5 (10.2) 
3 (42.9) 
.05 
*Total <75 due to missing data. 
* < 56 due to missing data. 
Table 1.  Distribution of microorganism isolated from the hip at different time frames. 
 
Microorganism 
Preoperative  
Culture (N=38) 
Intraoperative Culture on  
DOS Explant (N=52) 
Intraoperative Culture on  
Replant/Revision (N=51) 
N (%)  N (%)  N (%) 
E. coli  0  1 (1.9%)  0 
Enterococcus  0  3 (5.8%)  3 (5.9%) 
MSSA  4 (10.5%)  3 (5.8%)  0 
MRSA  1 (2.6%)  5 (9.6%)  1 (2.0%) 
Streptococcus (other)  6 (15.8%)  6 (11.5%)  0 
Micrococcus  1 (2.6%)  1 (1.9%)  0 
Proteus mirabilis  0  1 (1.9%)  0 
Corynebacterium  1 (2.6%)  1 (1.9%)  0 
S. Aureus/Peptosteptococcus  2 (5.3%)  0  0 
Streptococcus (β-hemolytic)/S. aureus   0  0  1 (2.0%) 
S. Aureus/Propionibacter  0  0  1 (2.0%) 
Staph (coagulase neg)  2 (5.3%)  6 (11.5%)  3 (5.9%) 
Bacillus sp. (not anthracis)  1 (2.6%)  1 (1.9%)  1 (2.0%) 
Propionibacter  3 (7.9%)  8 (15.4)  0 
Pseudomonas  1 (2.6%)  0  0 
S. saccharolyticus  0  0  1 (2.0%) 
S. aureus/E. coli/Morganella  0  0  1 (2.0%) 
No growth  16 (42.1%)  16 (30.8%)  39 (76.5%) 
Missing  18 (--)  4 (--)  5 (--) 
Any S. aureus  9 (23.7%)  14 (26.9%)  7 (13.7%) Treatment Failure Among Infected Periprosthetic Total Hip Arthroplasty Patients  The Open Orthopaedics Journal, 2014, Volume 8    123 
significance, those with lower WBC and PMN values prior to 
explant  appear  more  likely  to  have  a  successful  2
nd  stage 
procedure (p=0.10 and p=0.07, respectively) (Table 4). 
DISCUSSION 
  Periprosthetic  infection  after  total  hip  arthroplasty  is  a 
devastating  complication  that  increases  morbidity  for  the 
patient  and  cost  to  the  medical  system.  Today,  two-stage 
revision  surgery,  with  a  high-dose  antibiotic-laden  cement 
spacer, is regarded as the appropriate treatment protocol for 
chronic  periprosthetic  infections  after  THA  with  reported 
success rates of 80-90% [15, 16]. The ultimate goal of two-
stage revision surgery is to achieve a lasting eradication of 
the infection and a durable THA reconstruction. Eradication 
of the infection is achieved by implant extraction, debride-
ment and irrigation of the tissues, elution of antibiotics from 
the  polymethylmethacrylate  spacer,  and  administration  of 
systemic microorganism-specific, intravenous antibiotics. 
  Successful outcomes tend to be reported in the literature 
more  often  than  unsuccessful  ones;  treatment  of  peripros-
thetic  infection  is  no  exception.  Most  studies  report  the 
success  rate  among  patients  who  underwent  a  two-stage 
revision THA and do not include patients who were lost to 
follow-up or that did not reach the 2
nd stage of the procedure, 
thus eliminating a sub group of patients with poor outcomes. 
The purpose of the study was to report the success rate of 
two-stage  revision  THA  in  a  subpopulation  of  patients 
referred to a tertiary specialty hospital and to try to identify 
predictors  of  failure  to  eradicate  infections  and  of  poor 
outcome. 
  Our  results  are  similar  to  other  more  current  results 
reported  in  the  literature.  Biring  et  al.  reported  an  89% 
infection control rate after two-stage revision THA infection 
[17], and Wentworth et al. reported a success rate of 83% 
(success was defined as a negative culture take during the 2
nd 
stage procedure) [18]. These reported results are similar to 
the 91.1% infection eradication rate reported in our cohort. 
Most  studies  do  not  examine  the  success  of  two-stage 
revision surgery and eradication of infection separately. We 
have  subdivided  our  results  in  order  to  report  a  more 
meaningful success rate. Our combined success rate of both 
eradication of infection and long term survival of the two- 
 
stage revision surgery was 80.4%. In this group we do not 
include  patients  who  were  treated  with  suppression 
antibiotics (85.7% success of a two-stage revision THA was 
achieved if this subgroup was included) or patients who had 
resection arthroplasty (Girdlestone procedure). Parvizi et al. 
and Leung et al. [19, 20] showed a 75% and 79% infection 
control rate for methicillin-resistant Staphylococcus in two-
stage  THA  with  an  antibiotic  spacer,  respectively.  Berend  
et al.  in  a  study  of  202  patients  treated  with  a  two-stage 
procedure showed a 76% success rate in achieving infection 
eradication and a successful two-stage revision THA when 
they included the entire patient cohort, compared to an 83% 
success  rate  when  only  the  subgroup  of  patients  that 
underwent the second stage procedure were included [21]. 
Their data are similar to ours, and show that patients with 
more  virulent  organisms  or  higher  comorbidities  have  a 
slightly lower success rate for two-stage revision THA. 
  Another important finding in our series was the absence 
of  any  antibiotic  spacer  fractures;  spacer  fractures  are 
reported  in  the  literature  as  a  complication  of  two-stage 
revision surgery [17]. This emphasizes the importance of an 
endoskeleton to increase spacer strength and durability. 
  Over half of our cohort (63%) had more than one hip 
surgery prior to presentation at our institution; this reflects 
the complexity of the patient group. This was not found to be 
a significant predictor of failure. We did find that a history of 
another periprosthetic joint infection was highly predictive 
of failure of a two-stage THA revision procedure. This could 
point towards a patient group more susceptible to infection 
or harboring a more virulent organism. Practitioners should 
take  this  into  account  when  counseling  a  patient  with 
prosthetic joint infection and that has a history of a previous 
prosthetic joint infection in a different articulation. 
  Our study had a few limitations. First, our cohort is small 
and  is  derived  from  a  single  center.  Second,  due  to  the 
limited  sample  size,  we  were  unable  to  construct  a  more 
complex  analysis  model  to  examine  the  multitude  of 
variables  among  our  patients,  especially  the  influence  of 
medical  comorbidities.  Despite  these  limitations  our  study 
represents a consecutive single surgeon experience with two-
stage  revision  surgery  for  complicated  chronic  THA 
periprosthetic  infection  using  a  single  treatment  protocol, 
with  most  of  the  patients  (63%)  undergoing  multiple  hip 
surgeries prior to presentation. 
Table 4.  Association between patients’ age, BMI, and joint fluid markers, with 2
nd stage revision outcome. 
 
Variable 
2
nd Stage Success  2
nd Stage Failure 
p-Value 
N  Mean (SD)  Median (Range)  N  Mean (SD)  Median (Range) 
Age  48  61.9 (14.9)  62.2 (20.4-84.9)  8  65.0 (11.3)  58.9 (54.7-83.2)  .57* 
BMI  35  31.5 ( 8.4)  30.2 (19.0-48.0)  5  32.7 (10.0)  30.2 (23.8-47.6)  .77* 
ESR at reimplantation  42    26.5 (2.0-125.0)  5    25.0 (10.0-113.0)  .68** 
CRP at reimplantation  43    4.0 (0.08-489)  5    15.2 (0.17-28.5)  .48** 
WBC before explant  45    8.3 (3.0-23.8)  8    11.1 (4.9-22.8)  .10** 
PMN (%) before explant  43  72.0 (8.8)  71.4 (54.2-92.9)  8  78.4 (9.6)   74.1 (68.6-93.0)  .07* 
*t-test. 
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  The failure rate of simultaneous eradication of infection 
and successful two-stage revision observed in our series may 
be attributed to the specific patient characteristics typical of a 
referral center; such as multiple comorbidities and previous 
surgical  failures.  Factors  affecting  the  high  failure  rate 
observed  in  our  cohort  may  include  a  history  of  other 
previously infected prosthetic joints at any time during the 
patient’s past. We suggest that it is important to emphasize 
in current reports not only the infection eradication rate but 
also  the  total  success  of  the  two-stage  revision  surgery, 
which  should  include  both  the  successful  2
nd  stage 
reimplantation of the THA prosthesis as well as eradication 
of the infection. 
CONCLUSION 
  Patients  with  a  history  of  other  periprosthetic  joint 
infections have a lower rate of a successful outcome of two-
stage revision and should be counseled prior to the procedure 
on possible increased chance of treatment failure. 
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